Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

PGNY vs LFST vs HIMS vs GDRX vs TDOC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PGNY
Progyny, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$1.57B
5Y Perf.-67.5%
LFST
LifeStance Health Group, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$3.43B
5Y Perf.-72.8%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.+149.5%
GDRX
GoodRx Holdings, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$973M
5Y Perf.-92.1%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-95.8%

PGNY vs LFST vs HIMS vs GDRX vs TDOC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PGNY logoPGNY
LFST logoLFST
HIMS logoHIMS
GDRX logoGDRX
TDOC logoTDOC
IndustryMedical - Healthcare Information ServicesMedical - Care FacilitiesMedical - Equipment & ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$1.57B$3.43B$6.63B$973M$1.26B
Revenue (TTM)$1.29B$1.49B$2.35B$788M$2.51B
Net Income (TTM)$68M$23M$128M$29M$-171M
Gross Margin24.1%21.7%69.7%81.0%65.6%
Operating Margin7.5%3.0%4.6%12.4%-7.6%
Forward P/E16.4x121.1x51.5x9.0x
Total Debt$24M$194M$1.12B$60M$1.04B
Cash & Equiv.$112M$249M$229M$262M$781M

PGNY vs LFST vs HIMS vs GDRX vs TDOCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PGNY
LFST
HIMS
GDRX
TDOC
StockJun 21May 26Return
Progyny, Inc. (PGNY)10032.5-67.5%
LifeStance Health G… (LFST)10027.2-72.8%
Hims & Hers Health,… (HIMS)100249.5+149.5%
GoodRx Holdings, In… (GDRX)1007.9-92.1%
Teladoc Health, Inc. (TDOC)1004.2-95.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: PGNY vs LFST vs HIMS vs GDRX vs TDOC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PGNY and HIMS are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Hims & Hers Health, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. LFST and GDRX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
PGNY
Progyny, Inc.
The Income Pick

PGNY has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.

  • beta 0.71
  • Lower volatility, beta 0.71, Low D/E 4.7%, current ratio 2.73x
  • Beta 0.71, current ratio 2.73x
  • Beta 0.71 vs HIMS's 2.40, lower leverage
Best for: income & stability and sleep-well-at-night
LFST
LifeStance Health Group, Inc.
The Growth Play

LFST ranks third and is worth considering specifically for growth exposure.

  • Rev growth 13.9%, EPS growth 113.3%, 3Y rev CAGR 18.3%
  • +60.6% vs HIMS's -51.0%
Best for: growth exposure
HIMS
Hims & Hers Health, Inc.
The Long-Run Compounder

HIMS is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 161.9% 10Y total return vs PGNY's 20.2%
  • 59.0% revenue growth vs TDOC's -1.5%
  • 5.5% margin vs TDOC's -6.8%
Best for: long-term compounding
GDRX
GoodRx Holdings, Inc.
The Value Play

GDRX is the clearest fit if your priority is value.

  • Lower P/E (9.0x vs 51.5x)
Best for: value
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs TDOC's -1.5%
ValueGDRX logoGDRXLower P/E (9.0x vs 51.5x)
Quality / MarginsHIMS logoHIMS5.5% margin vs TDOC's -6.8%
Stability / SafetyPGNY logoPGNYBeta 0.71 vs HIMS's 2.40, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)LFST logoLFST+60.6% vs HIMS's -51.0%
Efficiency (ROA)PGNY logoPGNY9.0% ROA vs TDOC's -5.9%, ROIC 18.1% vs -11.5%

PGNY vs LFST vs HIMS vs GDRX vs TDOC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PGNYProgyny, Inc.
FY 2025
Fertility benefit services revenue
64.5%$831M
Pharmacy benefit services revenue
35.5%$458M
LFSTLifeStance Health Group, Inc.

Segment breakdown not available.

HIMSHims & Hers Health, Inc.

Segment breakdown not available.

GDRXGoodRx Holdings, Inc.
FY 2024
Prescription Transactions Revenue
84.3%$578M
Subscription Revenue
12.6%$87M
Other Revenue
3.1%$21M
TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M

PGNY vs LFST vs HIMS vs GDRX vs TDOC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPGNYLAGGINGLFST

Income & Cash Flow (Last 12 Months)

GDRX leads this category, winning 3 of 6 comparable metrics.

TDOC is the larger business by revenue, generating $2.5B annually — 3.2x GDRX's $788M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to TDOC's -6.8%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPGNY logoPGNYProgyny, Inc.LFST logoLFSTLifeStance Health…HIMS logoHIMSHims & Hers Healt…GDRX logoGDRXGoodRx Holdings, …TDOC logoTDOCTeladoc Health, I…
RevenueTrailing 12 months$1.3B$1.5B$2.3B$788M$2.5B
EBITDAEarnings before interest/tax$100M$100M$164M$184M$42M
Net IncomeAfter-tax profit$68M$23M$128M$29M-$171M
Free Cash FlowCash after capex$181M$179M$73M$132M$251M
Gross MarginGross profit ÷ Revenue+24.1%+21.7%+69.7%+81.0%+65.6%
Operating MarginEBIT ÷ Revenue+7.5%+3.0%+4.6%+12.4%-7.6%
Net MarginNet income ÷ Revenue+5.2%+1.6%+5.5%+3.7%-6.8%
FCF MarginFCF ÷ Revenue+14.0%+12.0%+3.1%+16.7%+10.0%
Rev. Growth (YoY)Latest quarter vs prior year+1.4%+21.2%+28.4%-4.4%-2.5%
EPS Growth (YoY)Latest quarter vs prior year+70.6%-27.3%-1.3%+32.1%
GDRX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

TDOC leads this category, winning 4 of 6 comparable metrics.

At 29.5x trailing earnings, PGNY trades at a 93% valuation discount to LFST's 442.5x P/E. On an enterprise value basis, GDRX's 4.0x EV/EBITDA is more attractive than HIMS's 42.7x.

MetricPGNY logoPGNYProgyny, Inc.LFST logoLFSTLifeStance Health…HIMS logoHIMSHims & Hers Healt…GDRX logoGDRXGoodRx Holdings, …TDOC logoTDOCTeladoc Health, I…
Market CapShares × price$1.6B$3.4B$6.6B$973M$1.3B
Enterprise ValueMkt cap + debt − cash$1.5B$3.4B$7.5B$771M$1.5B
Trailing P/EPrice ÷ TTM EPS29.48x442.50x50.32x33.29x-6.11x
Forward P/EPrice ÷ next-FY EPS est.16.39x121.07x51.51x8.98x
PEG RatioP/E ÷ EPS growth rate4.40x
EV / EBITDAEnterprise value multiple16.41x41.98x42.68x4.01x15.13x
Price / SalesMarket cap ÷ Revenue1.22x2.41x2.82x1.22x0.50x
Price / BookPrice ÷ Book value/share3.32x2.28x12.25x1.65x0.89x
Price / FCFMarket cap ÷ FCF8.18x31.20x89.61x5.92x4.40x
TDOC leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

PGNY leads this category, winning 5 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-12 for TDOC. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), LFST scores 7/9 vs HIMS's 4/9, reflecting strong financial health.

MetricPGNY logoPGNYProgyny, Inc.LFST logoLFSTLifeStance Health…HIMS logoHIMSHims & Hers Healt…GDRX logoGDRXGoodRx Holdings, …TDOC logoTDOCTeladoc Health, I…
ROE (TTM)Return on equity+13.3%+1.6%+23.7%+4.8%-12.4%
ROA (TTM)Return on assets+9.0%+1.1%+6.0%+1.9%-5.9%
ROICReturn on invested capital+18.1%+1.2%+10.7%+13.0%-11.5%
ROCEReturn on capital employed+17.4%+1.3%+10.9%+8.8%-10.0%
Piotroski ScoreFundamental quality 0–967466
Debt / EquityFinancial leverage0.05x0.13x2.07x0.10x0.75x
Net DebtTotal debt minus cash-$88M-$55M$892M-$202M$259M
Cash & Equiv.Liquid assets$112M$249M$229M$262M$781M
Total DebtShort + long-term debt$24M$194M$1.1B$60M$1.0B
Interest CoverageEBIT ÷ Interest expense3.30x3.61x-8.76x
PGNY leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $461 for TDOC. Over the past 12 months, LFST leads with a +60.6% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs TDOC's -35.6% — a key indicator of consistent wealth creation.

MetricPGNY logoPGNYProgyny, Inc.LFST logoLFSTLifeStance Health…HIMS logoHIMSHims & Hers Healt…GDRX logoGDRXGoodRx Holdings, …TDOC logoTDOCTeladoc Health, I…
YTD ReturnYear-to-date-25.6%+27.2%-23.2%+3.3%-1.3%
1-Year ReturnPast 12 months-18.2%+60.6%-51.0%-25.1%+1.5%
3-Year ReturnCumulative with dividends-45.0%+4.1%+116.6%-38.4%-73.3%
5-Year ReturnCumulative with dividends-62.9%-59.6%+137.6%-91.8%-95.4%
10-Year ReturnCumulative with dividends+20.2%-59.6%+161.9%-94.4%-41.1%
CAGR (3Y)Annualised 3-year return-18.1%+1.4%+29.4%-14.9%-35.6%
HIMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PGNY and LFST each lead in 1 of 2 comparable metrics.

PGNY is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFST currently trades 99.6% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPGNY logoPGNYProgyny, Inc.LFST logoLFSTLifeStance Health…HIMS logoHIMSHims & Hers Healt…GDRX logoGDRXGoodRx Holdings, …TDOC logoTDOCTeladoc Health, I…
Beta (5Y)Sensitivity to S&P 5000.71x1.06x2.40x1.58x1.91x
52-Week HighHighest price in past year$28.75$8.89$70.43$5.81$9.77
52-Week LowLowest price in past year$16.10$3.74$13.74$1.77$4.40
% of 52W HighCurrent price vs 52-week peak+66.6%+99.6%+36.4%+48.9%+71.2%
RSI (14)Momentum oscillator 0–10057.660.454.566.174.1
Avg Volume (50D)Average daily shares traded1.5M2.9M34.9M2.3M5.5M
Evenly matched — PGNY and LFST each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: PGNY as "Buy", LFST as "Buy", HIMS as "Hold", GDRX as "Hold", TDOC as "Hold". Consensus price targets imply 60.8% upside for PGNY (target: $31) vs 5.1% for LFST (target: $9).

MetricPGNY logoPGNYProgyny, Inc.LFST logoLFSTLifeStance Health…HIMS logoHIMSHims & Hers Healt…GDRX logoGDRXGoodRx Holdings, …TDOC logoTDOCTeladoc Health, I…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHoldHold
Price TargetConsensus 12-month target$30.80$9.30$29.67$3.19$7.58
# AnalystsCovering analysts2011192442
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+5.2%0.0%+1.4%+21.3%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

GDRX leads in 1 of 6 categories (Income & Cash Flow). TDOC leads in 1 (Valuation Metrics). 1 tied.

Best OverallProgyny, Inc. (PGNY)Leads 1 of 6 categories
Loading custom metrics...

PGNY vs LFST vs HIMS vs GDRX vs TDOC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PGNY or LFST or HIMS or GDRX or TDOC a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Progyny, Inc. (PGNY) offers the better valuation at 29. 5x trailing P/E (16. 4x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PGNY or LFST or HIMS or GDRX or TDOC?

On trailing P/E, Progyny, Inc.

(PGNY) is the cheapest at 29. 5x versus LifeStance Health Group, Inc. at 442. 5x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PGNY or LFST or HIMS or GDRX or TDOC?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus GDRX's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PGNY or LFST or HIMS or GDRX or TDOC?

By beta (market sensitivity over 5 years), Progyny, Inc.

(PGNY) is the lower-risk stock at 0. 71β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 239% more volatile than PGNY relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — PGNY or LFST or HIMS or GDRX or TDOC?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PGNY or LFST or HIMS or GDRX or TDOC?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -7. 9% for Teladoc Health, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PGNY or LFST or HIMS or GDRX or TDOC more undervalued right now?

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 0x forward P/E versus 121. 1x for LifeStance Health Group, Inc. — 112. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.

08

Which pays a better dividend — PGNY or LFST or HIMS or GDRX or TDOC?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is PGNY or LFST or HIMS or GDRX or TDOC better for a retirement portfolio?

For long-horizon retirement investors, Progyny, Inc.

(PGNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PGNY: +20. 2%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PGNY and LFST and HIMS and GDRX and TDOC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PGNY is a small-cap quality compounder stock; LFST is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; GDRX is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PGNY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

LFST

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 12%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

GDRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 48%
Run This Screen
Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PGNY and LFST and HIMS and GDRX and TDOC on the metrics below

Revenue Growth>
%
(PGNY: 1.4% · LFST: 21.2%)
P/E Ratio<
x
(PGNY: 29.5x · LFST: 442.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.